Leveraging CIRM Infrastructure to Improve Accessibility Panel - From left to right: Noah Federman, MD (moderator), Catriona Jamieson, MD, PhD, Mehrdad Abedi, MD, Daniela Bota, MD, PhD, Thomas Buchanan, MD, Brian Fury, MS, Dhruv Sareen, PhD, and Taby Ahsan, PhD The California Institute for Regenerative Medicine (CIRM) hosted the 7th Annual CIRM Alpha Clinics Network … Continue reading CIRM Showcases Strategic Vision and New Initiatives at 7th Annual Alpha Clinics Network Symposium
News
CIRM’s Key Recommendations from Strategic Allocation Framework
The California Institute for Regenerative Medicine (CIRM) presented key recommendations from its Strategic Allocation Framework (SAF), offering a structured, data‑driven approach to guide funding decisions and maximize impact. These recommendations, shared with the Independent Citizens’ Oversight Committee, move CIRM closer to its mission to accelerate the development and delivery of innovative regenerative medicine therapies. Evolving … Continue reading CIRM’s Key Recommendations from Strategic Allocation Framework
UC San Diego Gene Therapy Initiative Symposium fueling progress in the field
Enthusiasm ran high at the inaugural UC San Diego Gene Therapy Initiative Symposium at the Roth Auditorium at the Sanford Consortium. Researchers, clinicians, and patient advocates gathered to share new discoveries in gene therapy—a rapidly evolving field that is reshaping modern medicine. CIRM served as a platinum sponsor of the event. Era of progress The … Continue reading UC San Diego Gene Therapy Initiative Symposium fueling progress in the field
Strategic Framework Impacts the Future of CIRM’s Research Funding
As the regenerative medicine field rapidly evolves, CIRM faces a key challenge: investing the remaining $3.86 billion in ways that deliver the greatest impact for Californians. To meet this challenge, CIRM launched the Strategic Allocation Framework (SAF) to prioritize resources and maximize the potential of regenerative medicine breakthroughs. What is the SAF? The SAF uses … Continue reading Strategic Framework Impacts the Future of CIRM’s Research Funding
CIRM Supports Innovative Gene Therapy for Rare Heart Disorder
Image Source: American Heart Association Journals The California Institute for Regenerative Medicine (CIRM) awarded $4 million to support a gene therapy for rare life-threatening genetic disorder. A rare heart disorder Known as desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM), the genetic disorder is a rare heart disorder. This preclinical award went to Deborah D. Ascheim, … Continue reading CIRM Supports Innovative Gene Therapy for Rare Heart Disorder
CIRM awards boost clinical trials for cancer, heart, and rare diseases
The California Institute for Regenerative Medicine (CIRM) has allocated $26 million to support clinical research targeting cancers, heart conditions, and rare diseases. This investment reinforces CIRM’s commitment to advancing innovative stem cell and gene therapy treatments through all stages of clinical development. This round of awards funds five projects within CIRM’s Clinical Program, which provides … Continue reading CIRM awards boost clinical trials for cancer, heart, and rare diseases
Meet Our New CEO: Jonathan Thomas
We are thrilled to (re)introduce Jonathan Thomas (JT) as the new President and CEO of the California Institute for Regenerative Medicine (CIRM). You can check out the original press release here. We recently sat down with JT –who previously served as Chair of the Independent Citizens’ Oversight Committee (ICOC) as well as interim President and … Continue reading Meet Our New CEO: Jonathan Thomas
CIRM Welcomes Jonathan Thomas as New President and CEO
The California Institute for Regenerative Medicine (CIRM) is excited to announce the appointment of Jonathan “JT” Thomas, PhD, JD, as our new President and CEO. JT brings extensive experience and a deep commitment to our mission. Previously, he served as the Chair of the Independent Citizens' Oversight Committee (ICOC) for 12 years and, most recently, … Continue reading CIRM Welcomes Jonathan Thomas as New President and CEO
Transformative stem cell-based treatment for Cystic Fibrosis Sinusitis
A $6 million grant to Dr. Matthew Porteus and his team at Stanford University to develop an innovative stem cell-based gene correction therapy for chronic sinusitis in Cystic Fibrosis (CF) patients. CF is a common genetic disease that currently lacks a cure, causing patients to spend their lives managing symptoms. Despite significant advancements in CF … Continue reading Transformative stem cell-based treatment for Cystic Fibrosis Sinusitis
Supporting a CAR-T cell trial for kidney cancer
Photo Credit: Allogene Therapeutics. Image of the ALLO-316 allogeneic CAR-T cell therapy. The California Institute for Regenerative Medicine (CIRM) awarded $15 million to Dr. John Le Gall and his team at Allogene Therapeutics. This funding will support the development of ALLO-316, an innovative anti-CD70 CAR-T cell product designed to treat metastatic clear cell renal cell … Continue reading Supporting a CAR-T cell trial for kidney cancer